Osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (EGFR-TKI), has become a first-line treatment for non-small cell lung cancer (NSCLC) with EGFR mutations. This evidence concerns the gene EGFR and non-small cell lung carcinoma.